Agenda item 5, UNAIDS/PCB (43)/18.
11-13 December 2018 | Geneva, Switzerland
UNAIDS Programme Coordinating Board
Issue date: 23 November 2018
Saving Lives Through Safe Surgery (SaLTS)
Review Article
Granich et al. Int J Virol AIDS 2018, 5:043 DOI: 10.23937/2469-567X/1510043 Volume 5 | Issue 1
PlosOne https://doi.org/10.1371/journal.pone.0196799; Zoonotic diseases continue to be a public health burden globally. Uganda is especially vulnerable due to its location, biodiversity, and population. Given these concerns, the Ugandan government in collaboration with the Global Health Security Age...nda conducted a One Health Zoonotic Disease Prioritization Workshop to identify zoonotic diseases of greatest national concern to the Ugandan government.
more
ن عام 2017 ً كان فعال هو األكثر صعوبة على اإلطالق بين
األعوام التي سبقته. لقد سجل االقتصاد اليمني اطول انقطاع
في مرتبات موظفي الدولة، وأكبر انكماش تراكمي في الناتج
ال...محلي اإلجمالي، وأعلى زيادة في سعر صرف الدوالر، مع
نفاد االحتياطيات الخارجية وسط أزمة سيولة خانقة في القطاع
المصرفي.
Yemen Socio-Economic Update, Issue (30) December, 2017arabic
more
TB policies in 29 Countries
A survey of prevention, testing and treatment policies and practices
The study is based on in-depth, semi-structured qualitative interviews with 60 Syrians who arrived in Spain between 2015 and 2017.
Global Plan to end TB 2016-2020
Time for recognition of lay counsellors
Accessed November 2017
UNAIDS 2017 / Reference
Generating evidence for policy and action on HIV and social protection
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more